Last reviewed · How we verify
TWP-101
At a glance
| Generic name | TWP-101 |
|---|---|
| Also known as | Sytalizumab Injection |
| Sponsor | Shandong TheraWisdom Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor (PHASE1)
- Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TWP-101 CI brief — competitive landscape report
- TWP-101 updates RSS · CI watch RSS
- Shandong TheraWisdom Biopharma Co., Ltd. portfolio CI